I wouldn’t mind hearing from @Gumnut70 to give his current thoughts on DEP-Dudetaxel and the wider DEP program.
It was my contention for years that DEP-Dudetaxel was going nowhere, was likely to be a dud and would never commercialised. Gumnut70 however said I was completely clueless on the topic on a number of occasions, and he diligently and in detail explained to the forum why DEP-Dudetaxel was going to be a blockbuster and would revolutionise cancer treatment around the world. Cue a thunderous amount of thumbs up and insight bulbs.
However, subsequent to the recent underwhelming Phase 2 results (which were 5 years late), Starpharma in their webinar update have announced that DEP-Dudetaxel is being de-prioritised.
Just wondering @Gumnut70 (and others), what are your recalibrated thoughts are on the DEP program going forward.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)